https://orcid.org/0000-0002-0957-7389
![Sample our Engineering & Technology journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5933/TOC-Subject-Sample-2021-Engineering-Tech.jpg"})
Abstract
Purpose: This study investigated the prognostic performance of the systemic immune-inflammation index (SII) in patients with epithelial ovarian cancer (EOC) in Lagos, Nigeria. Methods: We performed a secondary analysis of the data of 91 women who had treatment for EOC between 2009 and 2018. The associations between pretreatment SII and survivals were tested. Results: Pretreatment SII more than 610.2 was a significant independent predictor of reduced progression-free survival (HR = 2.68; 95% CI, 1.17 to 6.09) while SII greater than 649.0 was a significant independent predictor of reduced 3-year overall survival (HR = 2.01; 95% CI, 1.01 to 3.99). Conclusion: These findings suggest that high SII may be a potential prognostic indicator and useful marker for more intensive surveillance and design of personalized treatment in patients with EOC.
Plain Language Summary
This study looked at how the systemic immune-inflammation index (SII) can predict the outcomes of patients with epithelial ovarian cancer (EOC). To do this, the data of 91 women who received treatment for EOC between 2009 and 2018 were analyzed. The study concluded that when the SII level was higher than 610.2 and 649.0, it was linked to a higher likelihood of EOC progressing sooner and of reduced survival at the 3-year mark, respectively. This suggests that a high SII might be a useful predictor to understand how EOC could progress and how well patients with EOC might survive.
Author contributions
All authors contributed to the study's conception and design. Material preparation, data collection and analysis were performed by KS Okunade, SO John-Olabode, AC Okoro, AA Adejimi and B Osunwusi. The first draft of the manuscript was written by KS Okunade and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Acknowledgments
We acknowledge all resident doctors in the Oncology and Pathological Studies Unit who assisted with the data collection for the primary study. We also appreciate the patients whose data were used in this study.
Financial & competing interests disclosure
The protected time of the lead author (KS Okunade) was supported by the National Cancer Institute and Fogarty International Center of the National Institutes of Health under award no. K43TW011930. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, Fogarty International Center, or the National Institutes of Health. The National Cancer Institute and Fogarty International Center of the National Institutes of Health had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. The study was granted an informed consent waiver by the Health Research Ethics Committee of the Lagos University Teaching Hospital before accessing the patients' datasets for analysis.